Cell Surface Markers Detection Market Extends at a Healthy CAGR of 8.60% by 2031

Introduction

Cell surface indicators allow us to distinguish between various cell types. Cell surface markers, which are proteins and carbohydrates attached to the cellular membrane, must function as an essential component of intercellular signaling. By examining the makeup of the cell surface indicators present in a particular cell, we can identify and distinguish it from the surrounding cells. T cells are categorized using common cell surface markers, including CD3, CD4, CD8, and CD25, into cytotoxic, helper, and regulatory T cells.

Market Dynamics

Rising Use in Diagnosis, Therapy, and Prognosis Drives the Global Market

The use of cell surface markers for treatment, diagnosis, and prognosis has gained popularity over the last few decades. Examining biomarkers in cancer patients before and after treatment is crucial to identify particular cell types that raise the risk of disease onset and subsequent post-therapeutic relapse. To understand the numerous interactions, cells must be distinguished from one another. Different cell types can be distinguished from one another using cell surface markers. Intercellular signaling depends on cell surface markers, proteins, and carbohydrates attached to the cellular membrane.

The presence of cell surface markers on a particular cell enables the detection and identification of the surrounding cell population. Common cell surface markers, including CD3, CD4, CD8, and CD25, are widely used to categorize T cells into their cytotoxic, helper, and regulatory T cell subclasses. Identifying the presence and quantity of particular cell types in a sample may impact decisions regarding diagnosis, clinical trial enrolment, therapeutic development, etc.

Technology Developments Associated with Higher Throughput and Automation Creates Tremendous Opportunities

Several methods can be used to identify the cell surface markers in a population of cells. Examples of ways that can be used to determine the cell surface indicators present in a population include immunohistochemistry (IHC), flow cytometry, and RNA sequencing (RNA-Seq). The businesses in the region are constantly improving their goods and introducing newer, more sophisticated ones that are precise and effective and can speed up laboratory workflow by automating several formerly labor-intensive and manually handled processes. This is because various technologies and devices used in the healthcare sector have become smaller due to technological breakthroughs.

For instance, in June 2020, Sysmex America Inc. unveiled its highly automated XF-1600 flow cytometer, improving the productivity and flexibility of laboratories. The business claims that the XF-1600 can also automate antibody staining, incubation, and flow cytometry analysis, giving users more confidence in the outcomes. Additionally, it offers seamless connectivity with the rest of the business's systems, including the PS-10 Sample Preparation System.

Regional Analysis 

North America is the most significant revenue contributor and is anticipated to expand at a CAGR of 8.80% over the projection period. The high prevalence of chronic diseases like cancer, cardiovascular diseases, and neurological disorders, among others, as well as the existence of a sizable number of research and development facilities across the country, are the main reasons why it is anticipated that the United States will hold a sizeable market share in the North American region over the forecast period in the market under study. For instance, according to the American Cancer Society, the nation would likely see 1,898,160 new cancer cases in 2021, along with 608,570 deaths. The future is anticipated to see a slight increase in this number.

Europe is anticipated to increase at a CAGR of 8.30% over the forecast period. Germany is one of the critical countries in the European region that invests the most substantially in R&D activities. Germany's market for the detection of cell surface markers is expected to grow throughout the study's prediction period due to several factors, including a high prevalence of diseases and a growing need for precision medicine. According to data from the Global Cancer Observatory (Globocan) for 2020, Germany recorded 628,519 new cancer cases. By 2040, this figure was projected to increase to 749,559 instances of cancer. The burden of cancer in the nation has increased significantly as a result. The country's studied market is expected to grow due to the predicted increase in demand for diagnostics and precision medicine.

Key Highlights

• The global cell surface markers detection market was valued at USD 4,940.40 million in 2022. It is projected to reach USD 10,380.79 million by 2031, growing at a CAGR of 8.60% during the forecast period (2023-2031).
• Based on the product, the global cell surface markers detection market is bifurcated into flow cytometry, hematology analyzers, and others. The flow cytometry segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.90% during the forecast period.
• Based on application, the global cell surface markers detection market is bifurcated into disease diagnosis and identification, drug discovery, and others. The drug discovery segment is the highest contributor to the market and is estimated to grow at a CAGR of 8.95% during the forecast period.
• North America is the primary significant revenue contributor and is expected to grow at a CAGR of 8.80% during the forecast period.

Competitive Players

Competitive Players

The global cell surface markers detection market's major key players are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), Becton, Dickinson and Company, Bio Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, Diasorin SpA (Luminex Corporation), Nihon Kohden Corporation, Qiagen NV, Siemens Healthineers, Thermo Fisher Scientific Inc., Grifols SA, and Nexcelom Bioscience LLC.

Recent Developments

Market News

• In April 2022, in the fields of hematology, urinalysis, and hemostasis, Sysmex Europe, a provider of automated workflow solutions, announced the launch of its Flow Cytometer XF-1600, which acquired CE marking, showing conformity with the European IVD Regulation and IVD use.
• In April 2022, Axion Bio subsidiary CytoSMART Technologies introduced the CytoSMART Omni FL, a next-generation live-cell imaging analysis system that, for the first time, adds red and green fluorescence channels to its renowned CytoSMART Omni product range. The development represents the company's continuous dedication to providing each cell biology lab with high-quality, affordable live-cell imaging. It provides a cutting-edge platform for researchers in stem cell biology, immuno-oncology, virology, toxicology, neurology, and other areas.

Segmentation

Global Cell Surface Markers Detection Market: Segmentation

By Product

• Flow Cytometry
• Hematology Analyzers
• Cell Imaging Systems
• Reagents and Kits
• Other Products

By Applications

• Disease Diagnosis and Identification
• Drug Discovery
• Others

By Regions

• North America
• Europe
• Asia-Pacific
• LAMEA